(RTTNews.com) - Eli Lilly and Co. (LLY) and Incyte Corp.( INCY) said that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of ...
WINDSOR LOCKS, Conn. — Low-cost carrier Breeze Airways will launch nonstop summer seasonal service between Bradley International Airport and Cincinnati/Northern Kentucky International Airport. The ...
Baricitinib displayed long-term effectiveness and safety in pediatric patients with atopic dermatitis (AD), recent study data show. The phase 3 study included 467 patients between ages 2 and 17. At ...
Please provide your email address to receive an email when new articles are posted on . Baricitinib met the primary endpoint in adults with moderate to severe atopic dermatitis in BREEZE-AD7, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback